Emily Whang1, Yuan Liu2,3, Shoichi Kageyama2, Shih Lung Woo4, Jieping Yang4, Rupo Lee4, Zhaoping Li4, Haofeng Ji2, Yijun Chen5, Jerzy W Kupiec-Weglinski6. 1. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, USA. ewhang@mednet.ucla.edu. 2. Division of Liver and Pancreas Transplantation, Department of Surgery, The Dumont-UCLA Transplantation Center, David Geffen School of Medicine, UCLA, 77-120 CHS, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA. 3. Division of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4. Center for Human Nutrition, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, USA. 5. Division of General Surgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA, 90095, USA. 6. Division of Liver and Pancreas Transplantation, Department of Surgery, The Dumont-UCLA Transplantation Center, David Geffen School of Medicine, UCLA, 77-120 CHS, 10833 Le Conte Ave., Los Angeles, CA, 90095, USA. jkupiec@mednet.ucla.edu.
Abstract
OBJECTIVE: To determine whether vertical sleeve gastrectomy (VSG) attenuates fibrosis in mice on a high-fat high-cholesterol (HFHC) diet. BACKGROUND: Bariatric surgery mitigates non-alcoholic steatohepatitis in 85-90% of obese patients. While animal models demonstrate similar results on a high-fat diet, none have observed the effects of bariatric surgery on a combined HFHC diet. METHODS: Mice on a HFHC diet were used to confirm the development of hepatic fibrosis at 8 (n = 15) and 24 (n = 15) weeks. A separate cohort of mice on a HFHC diet for 12 weeks was subjected to either VSG (n = 18) or sham (n = 12) operations and remained on a HFHC diet for an additional 20 weeks. Changes in weight, dyslipidemia, and the development of steatosis and fibrosis were documented. Serum was obtained for bile acid analysis by liquid chromatography and mass spectrometry, while hepatic gene expression by RT-PCR was performed to evaluate intrahepatic lipid metabolism. RESULTS: Hepatic steatosis and fibrosis developed after 8 weeks on the HFHC diet. After VSG, mice demonstrated a sustained decrease in weight with a significant decrease in fibrosis compared to sham mice. Serum total cholesterol, HDL, and LDL were significantly reduced following surgery, while serum bile acids were significantly elevated. Intra-hepatic cholesterol excretion was not upregulated based on hepatic gene expression of CYP7A1 and ABCG5/8. CONCLUSIONS: VSG attenuates the development of hepatic fibrosis in diet-induced obese mice, presumably through enhancement of cholesterol elimination at the intestinal level.
OBJECTIVE: To determine whether vertical sleeve gastrectomy (VSG) attenuates fibrosis in mice on a high-fat high-cholesterol (HFHC) diet. BACKGROUND: Bariatric surgery mitigates non-alcoholic steatohepatitis in 85-90% of obesepatients. While animal models demonstrate similar results on a high-fat diet, none have observed the effects of bariatric surgery on a combined HFHC diet. METHODS:Mice on a HFHC diet were used to confirm the development of hepatic fibrosis at 8 (n = 15) and 24 (n = 15) weeks. A separate cohort of mice on a HFHC diet for 12 weeks was subjected to either VSG (n = 18) or sham (n = 12) operations and remained on a HFHC diet for an additional 20 weeks. Changes in weight, dyslipidemia, and the development of steatosis and fibrosis were documented. Serum was obtained for bile acid analysis by liquid chromatography and mass spectrometry, while hepatic gene expression by RT-PCR was performed to evaluate intrahepatic lipid metabolism. RESULTS:Hepatic steatosis and fibrosis developed after 8 weeks on the HFHC diet. After VSG, mice demonstrated a sustained decrease in weight with a significant decrease in fibrosis compared to sham mice. Serum total cholesterol, HDL, and LDL were significantly reduced following surgery, while serum bile acids were significantly elevated. Intra-hepatic cholesterol excretion was not upregulated based on hepatic gene expression of CYP7A1 and ABCG5/8. CONCLUSIONS: VSG attenuates the development of hepatic fibrosis in diet-induced obesemice, presumably through enhancement of cholesterol elimination at the intestinal level.
Authors: Michael R Charlton; Justin M Burns; Rachel A Pedersen; Kymberly D Watt; Julie K Heimbach; Ross A Dierkhising Journal: Gastroenterology Date: 2011-07-02 Impact factor: 22.682
Authors: Margaret A Stefater; Darleen A Sandoval; Adam P Chambers; Hilary E Wilson-Pérez; Susanna M Hofmann; Ronald Jandacek; Patrick Tso; Stephen C Woods; Randy J Seeley Journal: Gastroenterology Date: 2011-05-18 Impact factor: 22.682
Authors: Mary-Elizabeth Patti; Sander M Houten; Antonio C Bianco; Raquel Bernier; P Reed Larsen; Jens J Holst; Michael K Badman; Eleftheria Maratos-Flier; Edward C Mun; Jussi Pihlajamaki; Johan Auwerx; Allison B Goldfine Journal: Obesity (Silver Spring) Date: 2009-04-09 Impact factor: 5.002
Authors: Limin Zhang; Cen Xie; Robert G Nichols; Siu H J Chan; Changtao Jiang; Ruixin Hao; Philip B Smith; Jingwei Cai; Margaret N Simons; Emmanuel Hatzakis; Costas D Maranas; Frank J Gonzalez; Andrew D Patterson Journal: mSystems Date: 2016-10-11 Impact factor: 6.496
Authors: Matthew Stevenson; Ankita Srivastava; Jenny Lee; Christopher Hall; Thomas Palaia; Raymond Lau; Collin Brathwaite; Louis Ragolia Journal: Obes Surg Date: 2021-04-15 Impact factor: 4.129